How You Could Benefit From Tax-Loss Selling This Year
The U.S. market gained more than 25% for the year to date through mid-December 2024
All Posts in "News Team"
Mister Car Wash Transferring Stock Listing to Nasdaq From NYSE
Mister Car Wash said it was transferring its stock listing from the New York Stock Exchange to the Nasdaq Global Select Market.
Sanofi’s $80M bet on Fulcrum’s dystrophy drug ends in phase 3 failure after 4 months
Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure.
European oncology organization extends clinical trial partnership with Medidata
The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is extending a partnership with Medidata for another four years, according to a Sept. 11 release.
GSK’s mRNA flu vaccine finally overcomes tricky B strains in phase 2 trial
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all-important population of older adults.
Lilly delivers one-two punch with 2nd tranche of positive data on weekly insulin candidate
Shortly after a positive data drop for Eli Lilly’s efsitora alfa, the Indianapolis-based company is again padding the case for its weekly insulin prospect.
Moderna targets $1.1B in R&D spending cuts, drops 5 programs amid profitability pressures
Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more selective and paced approach” to drug development.
Vironexis exits stealth with $26M, debuts rare disease gene therapies
Vironexis Biotherapeutics has unveiled with $26 million and a clinical-trial-ready gene therapy that has already nabbed FDA fast track and rare pediatric disease tags.
Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis
Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.
F2G raises $100M to fund 2nd attempt to get new antifungal class to market
After F2G’s first attempt to get a brand-new class of antifungal to market was derailed by the FDA, the U.K.-based biotech has secured $100 million in fresh funding to bankroll another push towards commercialization next year.
Weekly Market Review – December 21, 2024
Weekly Market Review – December 21, 2024
Medtronic appoints new chief medical officer for digital surgery and robotics
Neurocrine’s bid to save schizophrenia prospect fails
FDA greenlights over-the-counter hearing aid features for Apple’s AirPods
Oncternal folds all clinical trials after lackluster data drop, patient death
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs
FDA pushed to be more open, collaborative to accelerate rare disease R&D
In wake of Q2 revenue drop, Charles River cuts 3% of workforce
Inflammatix collects $57M as it awaits FDA review of infectious disease test